Home › Funds › Yorkville Advisors Global, LP › RNAZ
Yorkville Advisors Global, LP position in RNAZ
TransCode Therapeutics, Inc. · Health Care
Yorkville Advisors Global, LP reported holding 75,786 shares of RNAZ (TransCode Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$127K, representing 0.12% of its reported portfolio and ranking #33 among its reported holdings. Yorkville Advisors Global, LP has disclosed RNAZ holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Yorkville Advisors Global, LP's RNAZ position evolved
Yorkville Advisors Global, LP first disclosed a stake in RNAZ in Q2 2026 at 19,639 shares (US$122K). The position peaked in Q3 2026 at 75,786 shares, worth US$127K. Across 2 filings, Yorkville Advisors Global, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 75,786 shares valued at US$127K — an increase of 56,147 shares quarter over quarter.. Notable position changes include a 286% increase in Q3 2026 (shares fell 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 19.64K | $121.96K | New |
| Q3 2026 | 75.79K | $127.32K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNAZ and 13F data
RNAZ (TransCode Therapeutics, Inc.) is a Health Care company. 10 other funds we track also report a position in RNAZ. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on Yorkville Advisors Global, LP
FAQ
How long has Yorkville Advisors Global, LP held RNAZ?
Yorkville Advisors Global, LP has disclosed RNAZ holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Yorkville Advisors Global, LP's current position in RNAZ?
As of Q3 2026, Yorkville Advisors Global, LP holds 75.79K shares of RNAZ (TransCode Therapeutics, Inc.), valued at $127.32K, representing 0.12% of its reported portfolio and ranking #33.
Has Yorkville Advisors Global, LP been buying or selling RNAZ?
In the latest 13F filing (Q3 2026), Yorkville Advisors Global, LP increased its position in RNAZ. The position peaked in Q3 2026 at 75.79K shares.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.